AIP
MYOV

Ameritas Investment Partners’s Myovant Sciences Ltd. MYOV Stock Holding History

Ameritas Investment Partners’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-902
Closed -$11K – 3072
2017
Q1 		$11K Buy
+902
New +$10.3K ﹤0.01% 2668

Other funds holding MYOV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Ameritas Investment Partners's MYOV Position: Q2 2017 in Review

Ameritas Investment Partners sold out of Myovant Sciences Ltd. (MYOV) in Q2 2017, closing a stake of 902 shares — an estimated $11K sold.

Ameritas Investment Partners first reported a position in MYOV in Q1 2017 and held it in 1 quarter. The position peaked at $11K in Q1 2017. 42 funds tracked by Wall St. Rank hold MYOV as of Q2 2017.

  • Ameritas Investment Partners reported no remaining Myovant Sciences Ltd. position as of Q2 2017 after selling out during the quarter.
  • Ameritas Investment Partners sold 902 Myovant Sciences Ltd. shares in Q2 2017, an estimated $11K.
  • Ameritas Investment Partners first reported a position in Myovant Sciences Ltd. in Q1 2017 and held it in 1 quarter.
  • Ameritas Investment Partners's Myovant Sciences Ltd. position peaked at $11K in Q1 2017.
  • 42 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q2 2017.

Based on Ameritas Investment Partners's 13F filing for Q2 2017, filed 15 Aug 2017.